Skip to content

Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone

Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02734641
Enrollment
111
Registered
2016-04-12
Start date
2016-08-31
Completion date
2018-04-17
Last updated
2018-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Brief summary

The purpose of this study is to examine whether iron therapy in patients with intravenous iron deficiency anemia causes an increase in appetite. And whether this increase is mediated by the hormone ghrelin.

Detailed description

Prior to Iron treatment Investigator will sample subject blood for: counting blood, iron sector indices, renal function, electrolytes, and measure the level of ghrelin fasting plasma. In addition, the patient will fill a structured questionnaire that examines appetite levels. participants will be asked to answer a structured questionnaire which will include information on demographics, clinical data (fever, allergies, weight, height) and comorbidities. Additional data on laboratory tests, comorbidities, medication and regular blood and urine cultures results will be taken from the medical file. Iron treatment will be given according to local standard procedure . At the end of the treatment ghrelin levels and questionaire will be retaken . iron deficiency anemia is defined: hemoglobin \<12 gr / dl in women and Hb \<13 gr / dl in men with ferritin \<15 ng / ml.

Interventions

None listed

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects * sign and dated informed consent form.

Exclusion criteria

* chronic inflammatory disease. * chronic renal failure * active cancer. * active Infectious disease. * non iron deficiency anemia. * pregnancy.

Design outcomes

Primary

MeasureTime frame
Ghrelin levels after treatment with Intravenous Iron12 weeks

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026